

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA**

FRED BERGMAN HEALTHCARE PTY LTD. and
SIMAVITA (AUST) PTY LTD.,

Plaintiffs,

v.

SENECA SENSE TECHNOLOGIES INC.

Defendant.

C.A. No. _____

JURY TRIAL DEMANDED

COMPLAINT

Plaintiffs Fred Bergman Healthcare Pty Ltd. (“Bergman” or “Plaintiff”) and Simavita (Aust) Pty Ltd. (“Simavita” or “Plaintiff”) (collectively, “Plaintiffs”) hereby file this complaint against Defendant Seneca Sense Technologies Inc. (“Seneca Sense” or “Defendant”), and in support thereof, allege and aver as follows:

THE PARTIES

1. Bergman is an Australian proprietary limited company with a registered office at Level 2, 54 Miller Street, North Sydney NSW 2060, Australia. Bergman and Simavita are wholly owned subsidiaries of Simavita Limited.

2. Simavita is an Australian proprietary limited company with its principal place of business at Suite 2.02, Level 2, 54 Miller Street, North Sydney NSW 2060, Australia.

3. On information and belief, Seneca Sense is a corporation organized under the laws of Quebec, Canada, having its principal place of business at 2207 Rue Fullum, Montreal CA-QC Quebec H2K 3PI CA, and doing its business through its U.S. Agent, David Lennarz of Registrar Corp (“Registrar Corp”), at 144 Research Drive, Hampton, VA 23666.

4. On information and belief, Robert Tarasofsky (“Mr. Tarasofsky”) is a director of Seneca Sense.

5. On information and belief, Mr. Tarasofsky is President and Secretary of 7679149 Canada, Inc. (“7679149 Canada”), a corporation organized under the laws of Quebec, Canada, having its principal place of business at 1-4700 Rue Dagenais, Montreal CA-QC Quebec H4C1L7 CA.

6. On information and belief, Mr. Tarasofsky is a Canadian citizen domiciled at 469 Argyle Avenue, Westmount QC H3Y 3B3, Canada.

NATURE OF THE ACTION

7. This is a civil action arising, in part, under the patent laws of the United States, 35 U.S.C. § 1 et seq., including 35 U.S.C. § 271, based on Seneca Sense’s infringement of U.S. Patent No. 7,977,529 (“the ’529 Patent” or “Patent-in-Suit”) (Exhibit A) by virtue of its making, using, selling, offering for sale, and/or importing of Seneca Sense’s WeSense Technology into the United States.

JURISDICTION AND VENUE

8. This Court has subject matter jurisdiction over Counts I and II pursuant to 28 U.S.C. §§ 1331 and 1338(a) because the claims arise under the patent laws of the United States, 35 U.S.C. § 1 et seq., including 35 U.S.C. § 271.

9. This Court has personal jurisdiction over Seneca Sense pursuant to Fed. R. Civ. P. 4(k)(2) because (1) Plaintiffs’ claims arise under federal law; (2) Seneca Sense is a foreign corporation; and (3) Seneca Sense has sufficient contacts with the United States. Seneca Sense has filed an Establishment Registration & Device Listing with the U.S. Food and Drug Administration (“FDA”) and a Specific Absorption Report (“SAR”) with the Federal Communications Commission (“FCC”), and continues to conduct business directly or through its

subsidiaries, agents, and alter egos, including Registrar Corp., and thereby has purposefully availed itself to the benefits and protections of the laws of the Commonwealth of Virginia and the District Court for the Eastern District of Virginia. As such, Seneca Sense has sufficient minimum contacts with the forum state such that the maintenance of the suit does not offend traditional notions of fair play and substantial justice.

10. Venue is proper in this district under 28 U.S.C. §§ 1391(b) and 1400(b).

11. The accused infringing product is Seneca Sense's WeSense Technology, which includes, but is not limited to, the WeSense Wetness and Motion Detection System and the WeSense Pod and Sensor ("WeSense Technology").

12. On information and belief, Seneca Sense has conducted trials and pilots of its WeSense Technology in the United States and has offered its WeSense Technology for sale in the United States.

FACTUAL BACKGROUND

The Chronology of Events Leading to Infringement

13. Simavita (formerly known as Simavita Pty Ltd.) is a medical technology company that has, together with its related entities, been innovating for more than a decade on smart, wearable, and disposable platform technologies for the health care market. Plaintiffs' Smart Incontinence Management (SIM™) technology replaces traditional, manual methods for incontinence assessments with a unique automated system that helps facilities create customized care plans, which can help improve the management of incontinence, reduce falls, UTIs, and skin events while increasing quality of life and dignity for the aged.

14. Plaintiffs have developed new smart products for all segments of the incontinence market, including: 1) SIM™ ASSESS, an incontinence assessment system that collects and analyzes information about a user's continence status and includes i) a smart diaper with integrated

technology that allows for the detection of incontinence events during assessments ii) a reusable wireless data logging device SIM™ pod, iii) a smart tablet device; and iv) associated monitoring and planning software; and 2) SMARTZ™, a smart incontinence solution for day-to-day use, which delivers a host of wellness and wellbeing indicators, including wetness, ambient temperature, pressure sore management, and falls.

15. Although it was only recently that Plaintiffs learned of Seneca Sense's infringement of the '529 Patent, the relationship among Simavita, 7679149 Canada, Mr. Tarasofsky, and Seneca Sense started long ago.

16. Simavita first entered into an agreement with 7679149 Canada in May of 2011. The contract was an introducer agreement whereby 7679149 Canada and Mr. Tarasofsky, as President of 7679149 Canada, agreed to introduce prospective clients to Simavita for the purpose of commercializing Simavita's SIM™ diaper system in Canada, Japan, and the United States, hereafter referred to as the "2011 Introducer Agreement." Mr. Tarasofsky was identified as a "key person" under the 2011 Introducer Agreement.

17. Article 6.1 of the 2011 Introducer Agreement provides:

The Introducer acknowledges that Simavita is the licensee of, or the proprietor and rightful owner of the Intellectual Property and will not use any of the Intellectual Property for any purpose other than which is intended by the terms of this Agreement or as otherwise may be authorized in writing by Simavita.

18. Article 6.1 survived termination of the 2011 Introducer Agreement.


19. In 2012, Simavita and 7679149 Canada entered into a second introducer agreement. Simavita US, Inc. (a former related entity of Simavita) and 7679149 Canada entered into a consultancy agreement that sets forth 7679149 Canada and Mr. Tarasofsky's obligations, which included providing services, such as management and/or liaison services with a large prospective

US customer, Medline Industries, LP (“Medline”), as well as project management, conducting research, involvement in the evaluation of reference sites, and information gathering.

20. In October 2012, Simavita entered into a distribution agreement with Medline, whereby Medline agreed to distribute Simavita’s SIM™ ASSESS system to customers in the United States.

21. In 2013, Simavita obtained a 510(k) Premarket Notification for its SIM™ ASSESS system from the FDA:

510(k) Premarket Notification
 ● FDA Home ● Medical Devices ● Databases

 510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
 CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

[New Search](#) [Back To Search Results](#)

Device Classification Name	Alarm_Conditioned Response Enuresis
510(K) Number	K130951
Device Name	SIM
Applicant	SIMAVITA PTY LIMITED 555 13TH ST. NW Washington, DC 20004
Applicant Contact	John J Smith, Md,Jd
Correspondent	SIMAVITA PTY LIMITED 555 13TH ST. NW Washington, DC 20004
Correspondent Contact	John J Smith, Md,Jd
Regulation Number	876_2040
Classification Product Code	KPN
Date Received	04/05/2013
Decision Date	08/22/2013
Decision	Substantially Equivalent (SESE)
Regulation Medical Specialty	Gastroenterology/Urology
510K Review Panel	Gastroenterology/Urology
Summary	Summary
Type	Traditional
Reviewed By Third Party	No
Combination Product	No

See Simavita’s 510(k) Premarket Notification (available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K130951>).

22. From there, the relationship between Simavita and Mr. Tarasofsky grew and Mr. Tarasofsky and 7679149 Canada gained access to more and more of Simavita’s confidential information, such as key clients and its intellectual property. On January 1, 2014, Simavita and 7679149 Canada entered into a Services Agreement that gave Mr. Tarasofsky and his company additional insight into Simavita’s technology and business operations.

23. Conveniently, not long after Mr. Tarasofsky’s and Simavita’s relationship terminated, Seneca Sense started conducting trials and pilots of its competing WeSense Technology:



See SENECA SENSE, <https://www.senecasense.com/>.

24. On information and belief, at least some of Seneca Sense’s trials and pilots of WeSense Technology may have occurred in the United States.

25. In support of that belief, Plaintiffs present a series of intellectual property and regulatory filings that Seneca Sense filed in the United States. First, on May 31, 2018, Seneca Sense filed trademark registrations for both “Seneca Sense Technologies” and “We Sense.” The goods and services identified in these trademark filings include “sensors for measuring wetness” and “sensors for measuring wetness, namely, wearable liquid sensors for incontinence”:

SENECA SENSE TECHNOLOGIES	
Word Mark	SENECA SENSE TECHNOLOGIES
Goods and Services	IC 009. US 021 023 026 036 038. G & S: Sensors for measuring wetness, not for medical use. FIRST USE: 20190510. FIRST USE IN COMMERCE: 20190510
Standard Characters Claimed	
Mark Drawing Code	(4) STANDARD CHARACTER MARK
Serial Number	87942722
Filing Date	May 31, 2018
Current Basis	1A
Original Filing Basis	44D
Published for Opposition	December 3, 2019
Registration Number	6153764
Registration Date	September 15, 2020
Owner	(REGISTRANT) Seneca Sense Technologies Inc. CORPORATION CANADA 407 St. Laurent, Suite 500 Montreal, Quebec CANADA H2Y2Y5
Attorney of Record	BHARATI BAKSHANI
Priority Date	May 25, 2018
Disclaimer	NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "SENSE TECHNOLOGIES" APART FROM THE MARKAS SHOWN
Type of Mark	TRADEMARK
Register	PRINCIPAL
Live/Dead Indicator	LIVE

“*Seneca Sense Technologies,*” TRADEMARK ELECTRONIC SEARCH SYSTEM (TESS),
<https://www.uspto.gov/trademarks/search> (Exhibit B).

WE SENSE	
Word Mark	WE SENSE
Goods and Services	IC 009. US 021 023 026 036 038. G & S: Sensors for measuring wetness, namely, wearable liquid sensors for incontinence, not for medical use
Standard Characters Claimed	
Mark Drawing Code	(4) STANDARD CHARACTER MARK
Serial Number	87942658
Filing Date	May 31, 2018
Current Basis	44E
Original Filing Basis	44D
Published for Opposition	August 3, 2021
Registration Number	6522816
Registration Date	October 19, 2021
Owner	(REGISTRANT) Seneca Sense Technologies Inc. CORPORATION CANADA 407 St. Laurent, Suite 500 Montreal, Quebec CANADA H2Y2Y5
Attorney of Record	BHARATI BAKSHANI
Priority Date	May 25, 2018
Type of Mark	TRADEMARK
Register	PRINCIPAL
Live/Dead Indicator	LIVE

“*We Sense,*” TRADEMARK ELECTRONIC SEARCH SYSTEM (TESS),
<https://www.uspto.gov/trademarks/search> (Exhibit C).

26. On October 11, 2018, Seneca Sense continued to avail itself in the United States, and, specifically, the Commonwealth of Virginia, when Seneca Sense applied for registration from the FDA for its “WeSense Wetness and Motion Detection System”:

Establishment Registration & Device Listing	
● FDA Home ● Medical Devices ● Databases	
New Search Back To Search Results	
Proprietary Name:	Pod and Sensor; WeSense Wetness and Motion Detection System
Classification Name:	ALARM, CONDITIONED RESPONSE ENURESIS
Product Code:	KPN
Device Class:	2
Regulation Number:	876.2040
Medical Specialty:	Gastroenterology
Registered Establishment Name:	SENECA SENSE TECHNOLOGIES INC
Registered Establishment Number:	3014926187
Owner/Operator:	Seneca Sense Technologies Inc
Owner/Operator Number:	10058579
Establishment Operations:	Manufacturer

See Seneca Sense’s FDA Application (available at
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=588118&lpd=KPN>;
<https://fda.report/Company/Seneca-Sense-Technologies-Inc>).

27. In its FDA application for registration and device listing, Seneca Sense listed David Lennarz of Registrar Corp. as its United States agent. *Seneca Sense Technologies Inc. FDA Filings*, FDA.REPORT, <https://fda.report/Company/Seneca-Sense-Technologies-Inc>. Registrar Corp. assists businesses with U.S. FDA compliance issues for food products, medical devices, and drugs. *Registrar Corp.*, <https://www.registrarcorp.com>. Registrar Corp. has a principal place of business at 144 Research Drive, Hampton, Virginia 23666 USA.

28. Finally, in November 2019, Seneca Sense filed an application for equipment authorization with the FCC because its WeSense Technology System wirelessly communicates with a phone or tablet:

Applicant Information	
Applicant's complete, legal business name:	SENECA SENSE TECHNOLOGIES
FCC Registration Number (FRN):	0028942449
Alphanumeric FCC ID:	2AUYMWSP31
Unique Application Identifier:	8hagcExSMJfWvdxWz1XniQ==
Line one:	2207 FULLUM, MONTREAL, QUEBEC, CANADA
City:	QUEBEC
State:	N/A
Country:	Canada
TCB Information	
TCB Application Email Address:	bacl.regulatory@baclcorp.com
TCB Scope:	A4: UNII devices & low power transmitters using spread spectrum techniques
FCC ID	
Grantee Code:	2AUYM
Product Code:	WSP3-1

See Seneca Sense’s FCC Application (available at <https://fccid.io/2AUYMWSP3-1>).

29. Seneca Sense authorized Bay Area Compliance Laboratory Corporation to act on its behalf in all matters related to the FCC application for equipment authorization, stating in its application “[a]ll acts carried out by Bay Area Compliance Laboratory Corporation on our behalf shall have the same effect as our own action.” *Letter POA* in Seneca Sense’s FCC Application

(available at <https://fccid.io/document.php?id=4516130>). Bay Area Compliance Laboratory Corporation has a principal place of business at 1274 Anvilwood Ave., Sunnyvale, California 94089 USA.

30. Seneca Sense submitted a User Manual and photos of its WeSense Technology to the FCC in support of its authorization application. Included among the documents are test photos of a pod and user interface. However, these items are not branded with WeSense or Seneca Sense trademarks. Instead, they are branded with Medline's FitRight Connect trademark:




See Seneca Sense's FCC Application (available at <https://fccid.io/2AUYMWSP3-1>).

31. Medline is the owner of U.S. Trademark 8837618 "FITRIGHT CONNECT" for goods and services including incontinence briefs and sensors for detecting wetness in incontinence products:

FITRIGHT CONNECT	
Word Mark	FITRIGHT CONNECT
Goods and Services	IC 005. US 006 018 044 046 051 052. G & S: Incontinence briefs IC 010. US 026 039 044. G & S: Sensors for detecting wetness in incontinence products
Standard Characters Claimed	
Mark Drawing Code	(4) STANDARD CHARACTER MARK
Serial Number	88376148
Filing Date	April 8, 2019
Current Basis	1B
Original Filing Basis	1B
Published for Opposition	July 30, 2019
Owner	(APPLICANT) MEDLINE INDUSTRIES, LP LIMITED PARTNERSHIP ILLINOIS THREE LAKES DRIVE NORTHFIELD ILLINOIS 60093
Assignment Recorded	ASSIGNMENT RECORDED
Attorney of Record	Janet A. Marvel
Prior Registrations	4146810,4177116
Disclaimer	NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "CONNECT" APART FROM THE MARK AS SHOWN
Type of Mark	TRADEMARK
Register	PRINCIPAL
Live/Dead Indicator	LIVE

“*Fitright Connect*,” TRADEMARK ELECTRONIC SEARCH SYSTEM (TESS), <https://www.uspto.gov/trademarks/search> (Exhibit D).


32. FitRight is a Medline brand of products that include at least guards for men, underwear, liners, and briefs for the adult incontinence market space:




FitRight Ultra Adult Incontinence Underwear, MEDLINE,

<https://www.medline.com/product/FitRight-Ultra-Adult-Incontinence-Underwear/Absorbent-Underwear/Z05-PF62819?question=fitright>.

33. The relationship between Seneca Sense and Medline is even more obvious in Seneca Sense’s user interface photos. The tests and pilots in the photos, dated October 2019, are specifically named “Medline Test” and the FitRight application in Apple’s app store is listed as developed by Seneca Sense:



See Seneca Sense’s FCC Application (available at <https://fccid.io/2AUYMWSP3-1>).



See *Connect by FitRight by Seneca Sense Technologies Inc.*, APPLE STORE PREVIEW, <https://apps.apple.com/us/app/connect-by-fitright/id1581860467>.

34. On information and belief, Medline appears to be a customer of WeSense as of at least 2019.

35. In further support of Seneca Sense's activity in the United States, Seneca Sense hired an "Executive Vice President of Sales" located in Chicago, IL who "[j]oined Seneca Sense Technologies Inc. to support commercialization of WE SENSE™ in the United States."



Mitch Odahowski, LINKEDIN, <https://www.linkedin.com/in/mitchodahowski/>.

The Patent-in-Suit

36. The '529 Patent, titled "Incontinence Management System and Diaper," was issued by the United States Patent and Trademark Office ("USPTO") on July 12, 2011. Bergman is the lawful owner by assignment of the '529 Patent. Through a Technology License between Bergman and Simavita, Simavita is an exclusive licensee of the '529 Patent, including the right to sue for patent infringement and damages, including past damages.

The Technology of the Patent-in-Suit

37. The technology of the '529 Patent is a unique incontinence management system and sensor design, including a "smart" incontinence pad or diaper which delivers a host of wellness and well-being indicators including, but not limited to, wetness, ambient temperature, pressure sore management, falls, and many other features and information. The technology empowers caretakers with improved information and avoids unnecessary manual checking, which allows more time to spend on personalized care of residents and patients.

38. A sensing material is applied to or embedded into the diaper or incontinence product. This material most typically is on or near an outer surface of the diaper, is non-invasive, and is fully safe for skin contact. The pod gathers data from the pad sensor and it is securely encrypted and relayed wirelessly to a software application, where it can be viewed or transmitted onto a centralized system.

39. The wearers' status can be monitored via a dashboard of health and wellness metrics on an app or the data can be transmitted to existing resident monitoring and call systems, enabling the information to be displayed in one place.

Simavita's Smart Incontinence Pad or Diaper Product

40. Simavita is an international supplier of smart incontinence management systems, including smart incontinence pads and diaper products.

41. Since about 2013, Medline has sold Plaintiffs' SIM™ ASSESS system to customers in the United States, pursuant to its distributorship agreement with Simavita.

42. Plaintiffs' technology platform represents a clear unmet market need to provide low cost product to the growing US\$11bn market for adult incontinence pads (and the US\$53bn diaper market for infants). Plaintiffs' innovation disrupted both markets, where there has been a lack of disruptive innovation for over two decades.

43. Plaintiffs' technology incorporates sensors to measure fluid in a diaper, movement, temperature, and additional data to provide wellness data and warnings (important wellness indicators including pressure sore risks and falls) and this functionality will expand with product development.

Seneca Sense's Infringing Product

44. Seneca Sense is a Canadian company claiming to specialize in wearable technology. Specifically, Seneca Sense is in the adult brief sensing market aimed towards managing issues related to incontinence.

45. On information and belief, Seneca Sense currently offers one system: WeSense Technology.

46. WeSense Technology includes several components, including the WeSense Pod, WeSense printed sensor (either as an insert to add to an adult diaper, or as embedded sensor technology at the time of diaper manufacture), a commercially available incontinence product, and WeSense software application for a phone or tablet.

47. The WeSense Pod is a substantial component of WeSense Technology.

48. The WeSense Pod is especially made or especially adapted for use in WeSense Technology and is not a staple article or commodity of commerce suitable for substantial other uses.

49. WeSense Technology infringes at least claim 1 of the '529 Patent, which recites as follows:

1. A moisture monitoring system for monitoring wetness in one or more absorbent articles, the system including:

an input for receiving one or more sensor signals indicative of a presence of wetness in an absorbent article;

a processor; and

user interface for communicating with a user of the system;

wherein the processor executes an algorithm to analyze the one or more sensor signals by applying the one or more received sensor signals to a pre-determined mathematical model to characterize a wetness event in an absorbent article; and

wherein the system has devised the pre-determined mathematical model using sensor signal data previously received by the system, the mathematical model representing a relationship between one or more variables obtainable from the received sensor signals and a characteristic used to characterize a wetness event.

50. As required by Claim 1 of the '529 Patent, WeSense Technology is “[a] moisture monitoring system for monitoring wetness in one or more absorbent articles.”

The diagram consists of a small box on the left labeled "A System for Monitoring Wetness". Three arrows originate from this box and point to a larger box on the right. The larger box contains the WeSense logo (a teal four-leaf clover) and the text "WeSense". Below the logo is the tagline "The Easy Win-Win Solution for Real Time Care" and the heading "What is WeSense™?". A list of seven bullet points follows, with several terms highlighted in yellow: "disposable sensor", "commercially available incontinence product", "POD", "wetness alerts", "App", and "Data that helps to plan staffing needs and budgets".

WeSense


The Easy Win-Win Solution for Real Time Care

What is WeSense™?

- A disposable sensor is placed in any commercially available incontinence product.
- The sensor is inserted into a POD, which is a connected wearable device that senses wetness events.
- The device (POD) transmits individual wetness alerts to an App for care aids to act on.
- This invaluable tool can reduce costs & penalties for care facilities.
- Brief changes are made at appropriate times offering the highest level of care to residents.
- Faster service delivery, less time spent in a wet brief.
- Software that manages all data for reporting and verification. Data that helps to plan staffing needs and budgets.

See, e.g., *What is WeSense?*, SENECA SENSE, <https://www.senecasense.com/what-is-wesense/>.

51. WeSense Technology is a system including “an input for receiving one or more sensor signals indicative of a presence of wetness in an absorbent article.”





WeSense


The Easy Win-Win Solution for Real Time Care

What is WeSense™?

- A disposable sensor is placed in any commercially available incontinence product.
- **The sensor is inserted into a POD, which is a connected wearable device that senses wetness events.**
- The device (POD) transmits individual wetness alerts to an App for care aids to act on.
- This invaluable tool can reduce costs & penalties for care facilities.
- Brief changes are made at appropriate times offering the highest level of care to residents.
- Faster service delivery, less time spent in a wet brief.
- Software that manages all data for reporting and verification. Data that helps to plan staffing needs and budgets.


Id.

52. WeSense Technology is a system including “a processor.” For example, the processor can be a phone, computer, tablet, or existing hospital monitoring system capable of downloading the WeSense or FitRight Applications:




Id.

53. The WeSense Pod also includes a processor:




See Seneca Sense's FCC Application (available at <https://fccid.io/2AUYMWSP3-1>).

54. WeSense Technology is a system including a “user interface for communicating with a user of the system.”



Id.

55. WeSense Technology is a system “wherein the processor executes an algorithm to analyze the one or more sensor signals by applying the one or more received sensor signals to a pre-determined mathematical model to characterize a wetness event in an absorbent article.”



Id.


56. WeSense Technology is a system “wherein the system has devised the pre-determined mathematical model using sensor signal data previously received by the system, the mathematical model representing a relationship between one or more variables obtainable from the received sensor signals and a characteristic used to characterize a wetness event.” Among the information provided on the user interface of the WeSense Technology are green, yellow, and red

indicators reflecting the status and capacity of the brief on the wearer. This type of functionality evidences the presence of a mathematical model against which the sensors are calibrated.




What is WeSense?, SENECA SENSE, <https://www.senecasense.com/what-is-wesense/>.

57. WeSense Technology has a WeSense Pod designed to connect to a WeSense sensor once it is placed in an incontinence brief:



See Seneca Sense’s FCC Application (available at <https://fccid.io/2AUYMWSP3-1>).

58. The WeSense Pod connects to the WeSense printed sensor to send a signal over Wi-Fi, Bluetooth, radio, or an analogous means of wireless communication to the smart application on a phone or tablet. The application “WeSense” is downloadable in the United States based Apple App Store:



See *WeSense* by *Seneca Sense Technologies Inc.*, APPLE STORE PREVIEW, <https://apps.apple.com/us/app/wesense/id1582524117>.

59. WeSense Technology is designed to detect wetness in the brief to help reduce the time users wear a wet brief:

How it works

WeSense™ will detect wetness events in real time and will alert when the brief is close to usable capacity. This way, caregivers will change residents at the appropriate time! Caregivers can rely on accurate data to change residents when alerted. **Not too soon, not too late but at the right time!**

WeSense™ provides usage patterns and analysis in order to help plan your staff's workload and help in choosing the most suitable incontinence product for each resident. As a result your staff members will never have to physically check a resident's incontinence product for saturation ever again while using WeSense™.*

See *What is WeSense?*, SENECA SENSE, <https://www.senecasense.com/what-is-wesense/>.

COUNT I:

Infringement of the '529 Patent by Seneca Sense Pursuant to 35 U.S.C. § 271(a)

60. Plaintiffs incorporate by reference the allegations in Paragraphs 1 through 59 above.

61. The '529 Patent is directed to an “incontinence management system for monitoring wetness in one or more absorbent articles.” (Exhibit A at Abstract).

62. As set forth in Paragraphs 44-59 and pursuant to 35 U.S.C. § 271(a), after conducting a reasonable investigation, Seneca Sense has infringed at least Claim 1 of the '529 Patent, either literally or under the doctrine of equivalents, by making, using, selling, offering for sale, and/or importing WeSense Technology in and/or from the United States.

63. On information and belief, Seneca Sense has conducted trials and/or pilots of its infringing WeSense Technology in the United States:



See SENECA SENSE, <https://www.senecasense.com/>.

64. On information and belief, Seneca Sense has offered its WeSense Technology for sale in the United States.

65. In light of the foregoing, Seneca Sense has infringed the '529 Patent in violation of at least 35 U.S.C. § 271(a).

66. Plaintiffs have been damaged as a result of Seneca Sense's past use and/or offering for sale of WeSense Technology in the United States.

67. Plaintiffs are being damaged as a result of Seneca Sense's current use, manufacture, import, sale, and/or offer for sale of WeSense Technology in the United States.

68. Plaintiffs will be damaged as a result of Seneca Sense's future use, manufacture, import, sale, and/or offer for sale of WeSense Technology in the United States.

69. Thus, Seneca Sense is liable to Plaintiffs in an amount that compensates it for such infringement, which by law cannot be less than a reasonable royalty, together with interest and costs as fixed by this Court under 35 U.S.C. § 284.

70. On information and belief, Seneca Sense has acted with full knowledge of the '529 Patent and without a reasonable basis for believing that it was not or would not be liable for infringing the '529 Patent. On further information and belief, Seneca Sense's infringement has been willful under 35 U.S.C. § 284.

71. Seneca Sense's infringement of the '529 Patent will result in loss of market share for Plaintiffs' products.

72. Seneca Sense's infringement of the '529 Patent has and will disrupt Plaintiffs' customer relationships and contracts. Such disruption has and will result in the formation of customer relationships between Seneca Sense and Plaintiffs' existing customers, the adverse effects of which cannot be adequately compensated by money damages.

73. The injury to Plaintiffs in light of the foregoing cannot be adequately compensated by money damages, and is irreparable.

COUNT II:

Infringement of the '529 Patent by Seneca Sense Pursuant to 35 U.S.C. § 271(b)-(c)

74. Plaintiffs incorporate by reference the allegations in Paragraphs 1 through 73 above.

75. On information and belief, after conducting a reasonable investigation, Seneca Sense has and is actively, knowingly, and intentionally aiding and abetting and inducing infringement of the '529 Patent in violation of 35 U.S.C. § 271(b) by non-parties, including customers and end-users, despite Seneca Sense's knowledge of the '529 Patent.

76. On information and belief, Seneca Sense has taken and continues to take active steps to encourage and induce customers to infringe the '529 Patent by developing and offering a FitRight branded smart diaper system that utilizes Seneca Sense's WeSense Technology.

77. On information and belief, Seneca Sense has actual knowledge of, or at a minimum was willfully blind to, the fact that customers and end-users of its WeSense Technology have infringed, and will continue to infringe, at least one claim of the '529 Patent.

78. On information and belief, Seneca Sense is contributing to the infringement of the '529 Patent in violation of 35 U.S.C. § 271(c) by using, offering to sell, or selling within the United

States or importing into the United States components of the patented invention set forth in at least claim 1 of the '529 patent. The components constitute a material part of the invention claimed in the '529 patent. Seneca Sense knows that such components are especially made or especially adapted for use by customers and end-users in an infringement of at least claim 1 of the '529 Patent. The components are not a staple article or commodity of commerce suitable for substantial non-infringing use.

79. By reason of Seneca Sense's infringing activities, Plaintiffs have suffered, and will continue to suffer, substantial damages in an amount to be proven at trial.

80. Seneca Sense's acts complained of herein have damaged and will continue to damage Plaintiffs irreparably.

81. Seneca Sense is not licensed or otherwise authorized to make, use, import, sell, or offer to sell any Smart Incontinence Pad, software application, sensor pod, or Diaper Product claimed in the '529 Patent, and Seneca Sense's conduct is, in every instance, without Plaintiffs' consent.

82. On information and belief, Seneca Sense's infringement has been and continues to be with full knowledge of the '529 Patent and willful under 35 U.S.C. § 284.

CONCLUSION AND PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that:

- A. The Court find that the Defendant has infringed the Patent-in-Suit and hold the Defendant liable for such infringement under 35 U.S.C. § 271(a)-(c);
- B. The Court issue an order pursuant to 35 U.S.C. § 284 for monetary damages in an amount no less than a reasonable royalty to adequately compensate Plaintiffs for Defendant's infringement of the Patent-in-Suit;


- C. The Court issue an order pursuant to 35 U.S.C. § 283 permanently enjoining the Defendant, and anyone acting or participating by, through or in concert with the Defendant, from infringing the Patent-in-Suit;
- D. The Court declare that Defendant's infringement has been willful and that this is an exceptional case entitling Plaintiffs to their reasonable attorneys' fees under 35 U.S.C. § 285;
- E. The Court award Plaintiffs their costs and reasonable attorneys' fees; and
- F. The Court award such other relief as the court may deem just and proper.

DEMAND FOR JURY TRIAL

Plaintiffs hereby demand a trial by jury on all issues so triable.

Dated: December 9, 2021

K&L GATES LLP



Amy J. Eldridge, Esq. (VSB # 77873)

K&L Gates LLP

1601 K Street NW

Washington, DC 20006

Telephone: 202-778-9400

Fax: 202-778-9100

Email: amy.eldridge@klgates.com

Jeffrey R. Gargano (*pro hac vice* forthcoming)

Devon C. Beane (*pro hac vice* forthcoming)

Amanda C. Maxfield (*pro hac vice* forthcoming)

K&L Gates LLP

70 West Madison Street, Suite 3300

Chicago, Illinois 60602

Telephone: (312) 372-1121

Fax: (312) 827-8000

Email: jeffrey.gargano@klgates.com

devon.beane@klgates.com

amanda.maxfield@klgates.com

*Attorneys for Plaintiffs Fred Bergman Healthcare
Pty Ltd. and Simavita (Aust) Pty Ltd.*